Polyprenyl Immunostimulant: findings in mice and human cells, with limited direct evidence on FeLV

Cells · 2025

In plain language

The study found changes in some substances and immune cells after exposure to Polyprenyl Immunostimulant (PI) in mice and human cells. These results do not demonstrate improved immune defenses in cats with FeLV. The only direct FeLV observation involved one cat with another infection at the same time, in which progressive FeLV infection persisted. That case had no comparison group and involved several agents, so it cannot establish the effect of PI.

Scientific detail

The article published in Cells in 2025 (doi: 10.3390/cells14100752) presents experiments in mice and human THP-1 cells, alongside one feline case. The methods describe eight female CD-1 retired breeder mice previously used in a PI toxicity study; the Figure 5 caption specifies two untreated, three vehicle-exposed and three PI-exposed mice. Separately, the results describe ten female C57/Bl6 mice, with five per arm in Figure 6. THP-1 biological replicate counts are not reported in the visible text. Part of the supplied source is omitted, preventing assessment of the complete methods and results.

Metabolomic analyses identified sphinganine and ceramide as common metabolites whose levels increased in association with PI exposure in THP-1 cells and mice. This non-feline biochemical finding does not demonstrate the same response in FeLV-infected cats, identify a direct molecular target or establish improved antiviral function. The authors acknowledge that metabolomics was performed at a single concentration and a single time point, and that further experiments are needed to support involvement of the proposed pathways and identify molecular targets.

In the mouse experiments, PI exposure did not significantly alter bone marrow or splenic hematopoietic stem and progenitor cell populations. This is an absence of a statistically significant population change under the tested conditions, not proof of an absence of hematopoietic effects or of restoration of FeLV-associated bone marrow dysfunction. Bone marrow immunophenotyping showed lower percentages of B cells and CD8+ cells and increased CD4+ cells after PI exposure. These shifts in cell distribution, including a higher CD4+/CD8+ ratio, do not by themselves establish stronger immune function, antiviral protection or reversal of feline immunosuppression. All four findings represented in the object's claims carry evidence level D.

Mice and THP-1 cells were studied under pathogen-free conditions, not in FeLV-infected feline immune cells. Their application to FeLV-associated immunosuppression is therefore inferential. The only direct FeLV observation concerns a single co-infected cat in which progressive FeLV infection persisted. The cat was a stray with an unknown history; the observation had no control and involved multiple agents. Comparison with durations reported for other cats was not a concurrent controlled comparison.

What we know

At evidence level D, experiments in mice and human THP-1 cells show PI-associated increases in sphinganine and ceramide. Mice showed changes in the distribution of bone marrow B cells, CD8+ cells and CD4+ cells, with no statistically significant changes in bone marrow or splenic hematopoietic stem and progenitor cell populations. Metabolomics was limited to one concentration and one time point. Progressive infection persisted in the only cat providing a direct FeLV observation; the case had no control and involved multiple agents.

What we don't know

It is not established whether the observed biochemical and immune changes also occur in FeLV-infected cats, or whether they improve antiviral function or reverse FeLV-associated immunosuppression or bone marrow dysfunction. The proposed pathways remain incompletely characterized, and direct molecular targets have not been identified. The feline case cannot isolate the effect of PI. THP-1 biological replicate counts are not reported in the visible text, and the omission of part of the source prevents assessment of the complete methods and results.

Evidence

Provenance

This project does not diagnose or prescribe. Always consult your veterinarian.